Top

Published in:

Open Access 01-08-2024 | Neuroblastoma | Original Paper

Molecular pathway of anticancer effect of next-generation HSP90 inhibitors XL-888 and Debio0932 in neuroblastoma cell line

Authors: Özlem Kaplan, Nazan Gökşen Tosun

Published in: Medical Oncology | Issue 8/2024

Abstract

Neuroblastoma is a common nervous system tumor in childhood, and current treatments are not adequate. HSP90 is a molecular chaperone protein that plays a critical role in the regulation of cancer-related proteins. HSP90 inhibition may exert anticancer effects by targeting cancer-related processes such as tumor growth, cell proliferation, metastasis, and apoptosis. Therefore, HSP90 inhibition is a promising strategy in the treatment of various types of cancer, and the development of next-generation inhibitors could potentially lead to more effective and safer treatments. XL-888 and Debio0932 is a next-generation HSP90 inhibitor and can inhibit the correct folding and stabilization of client proteins that cancer-associated HSP90 helps to fold correctly. In this study, we aimed to investigate the comprehensive molecular pathways of the anticancer activity of XL-888 and Debio0932 in human neuroblastoma cells SH-SY5Y. The cytotoxic effects of XL-888 and Debio0932 on the neuroblastoma cell line SH-SY5Y cells were evaluated by MTT assay. Then, the effect of these HSP90 inhibitors on the expression of important genes in cancer was revealed by Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) method. The qRT-PCR data were evaluated using Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) biological process tools. Finally, the effect of HSP90 inhibitors on HSP27, HSP70 and HSP90 protein expression was investigated by Western blotting analysis. The results revealed that XL-888 and Debio0932 had a role in regulating many cancer-related pathways such as migration, invasion, metastasis, angiogenesis, and apoptosis in SH-SY5Y cells. In conclusion, it shows that HSP90 inhibitors can be considered as a promising candidate in the treatment of neuroblastoma and resistance to chemotherapy.

Qiao J, Lee S, Paul P, Qiao L, Taylor CJ, Schlegel C, et al. Akt2 regulates metastatic potential in neuroblastoma. PLoS ONE. 2013;8:e56382.CrossRefPubMedPubMedCentral

Gerges A, Canning U. Neuroblastoma and its target therapies: a medicinal chemistry review. ChemMedChem. 2023. https://doi.org/10.1002/cmdc.202300535.CrossRef

Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022;19:515–33.CrossRefPubMed

Magwenyane AM, Ugbaja SC, Amoako DG, Somboro AM, Khan RB, Kumalo HM. Heat shock protein 90 (HSP90) inhibitors as anticancer medicines: a review on the computer-aided drug discovery approaches over the past 5 years. Comput Math Methods Med. 2022;2022:2147763. https://doi.org/10.1155/2022/2147763.CrossRefPubMedPubMedCentral

Kaplan Ö. Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888. Med Oncol. 2023;40:318. https://doi.org/10.1007/s12032-023-02181-9.CrossRefPubMed

Gökşen TN. Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100. Naunyn Schmiedebergs Arch Pharmacol. 2023. https://doi.org/10.1007/s00210-023-02807-9.CrossRef

Luyao F, Xin T. Mechanism of HSP90 inhibitor AUY-922 reversing ALK inhibitor resistance in human neuroblastoma cells. Cancer Res Prev Treat. 2022;49:294–8.

McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, et al. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation. BMC Cancer. 2017;17:86. https://doi.org/10.1186/s12885-017-3084-0.CrossRefPubMedPubMedCentral

Bussenius J, Blazey CM, Aay N, Anand NK, Arcalas A, Baik T, et al. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Bioorg Med Chem Lett. 2012;22:5396–404. https://doi.org/10.1016/j.bmcl.2012.07.052.CrossRefPubMed

10.

Zhang Y, Ware MB, Zaidi MY, Ruggieri AN, Olson BM, Komar H, et al. Heat shock protein-90 inhibition alters activation of pancreatic stellate cells and enhances the efficacy of PD-1 blockade in pancreatic cancer. Mol Cancer Ther. 2021;20:150–60. https://doi.org/10.1158/1535-7163.Mct-19-0911.CrossRefPubMed

11.

Vido MJ, Aplin AE. The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox. J Investig Dermatol. 2015;135:2355–7. https://doi.org/10.1038/jid.2015.239.CrossRefPubMed

12.

Stenderup K, Rosada C, Gavillet B, Vuagniaux G, Dam TN. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol. 2014. https://doi.org/10.2340/00015555-1838.CrossRefPubMed

13.

Isambert N, Delord J-P, Soria J-C, Hollebecque A, Gomez-Roca C, Purcea D, et al. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase. Ann Oncol. 2015;26:1005–11.CrossRefPubMed

14.

Gökşen Tosun N, Erden Tayhan S, Gökçe İ, Alkan C. Doxorubicin-loaded mPEG-pPAd-mPEG triblock polymeric nanoparticles for drug delivery systems: Preparation and in vitro evaluation. J Mol Struct. 2023;1291:135959. https://doi.org/10.1016/j.molstruc.2023.135959.CrossRef

15.

Kaplan Ö, Gök MK, Pekmez M, Erden Tayhan S, Özgümüş S, Gökçe İ, et al. Development of recombinant protein-based nanoparticle systems for inducing tumor cell apoptosis: in vitro evaluation of their cytotoxic and apoptotic effects on cancer cells. J Drug Deliv Sci Technol. 2024;95:105565. https://doi.org/10.1016/j.jddst.2024.105565.CrossRef

16.

Özgür A, Kaplan Ö, Gökşen Tosun N, Türkekul İ, Gökçe İ. Green synthesis of silver nanoparticles using Macrolepiota procera extract and investigation of their HSP27, HSP70, and HSP90 inhibitory potentials in human cancer cells. Part Sci Technol. 2023;41:330–40. https://doi.org/10.1080/02726351.2022.2089303.CrossRef

17.

Hanna R, Abdallah J, Abou-Antoun T. A novel mechanism of 17-AAG therapeutic efficacy on HSP90 inhibition in MYCN-amplified neuroblastoma cells. Front Oncol. 2021;10:624560.CrossRefPubMedPubMedCentral

18.

Thapa K, Khan H, Kaur G, Kumar P, Singh TG. Therapeutic targeting of angiopoietins in tumor angiogenesis and cancer development. Biochem Biophys Res Commun. 2023;687:149130. https://doi.org/10.1016/j.bbrc.2023.149130.CrossRefPubMed

19.

Zhang PC, Liu X, Li MM, Ma YY, Sun HT, Tian XY, Wang Y, Liu M, Fu LS, Wang YF, Chen HY. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo. Biochem Pharmacol. 2020. https://doi.org/10.1016/j.bcp.2019.113771.CrossRefPubMedPubMedCentral

20.

Troy CM, Rabacchi SA, Hohl JB, Angelastro JM, Greene LA, Shelanski ML. Death in the balance: alternative participation of the caspase-2 and-9 pathways in neuronal death induced by nerve growth factor deprivation. J Neurosci. 2001;21:5007–16.CrossRefPubMedPubMedCentral

21.

Shakeri R, Kheirollahi A, Davoodi J. Contribution of Apaf-1 to the pathogenesis of cancer and neurodegenerative diseases. Biochimie. 2021;190:91–110. https://doi.org/10.1016/j.biochi.2021.07.004.CrossRefPubMed

22.

Kim S, Kang J, Hu W, Evers BM, Chung DH. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer. 2003;103:352–9. https://doi.org/10.1002/ijc.10820.CrossRefPubMed

23.

Hsu J, Sage J. Novel functions for the transcription factor E2F4 in development and disease. Cell Cycle. 2016;15:3183–90. https://doi.org/10.1080/15384101.2016.1234551.CrossRefPubMedPubMedCentral

24.

Sun Y, Cheng Z, Liu S. MCM2 in human cancer: functions, mechanisms, and clinical significance. Mol Med. 2022;28:128. https://doi.org/10.1186/s10020-022-00555-9.CrossRefPubMedPubMedCentral

25.

Zhang X, Teng Y, Yang F, Wang M, Hong X, Ye LG, et al. MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas. Oncol Rep. 2015;33:2599–605. https://doi.org/10.3892/or.2015.3822.CrossRefPubMed

26.

Wang B, Wang Z, Han L, Gong S, Wang Y, He Z, et al. Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis. Cancer Cell Int. 2019;19:158. https://doi.org/10.1186/s12935-019-0865-3.CrossRefPubMedPubMedCentral

27.

Chen H, Hu J, Xiong X, Chen H, Lin B, Chen Y, et al. AURKA inhibition induces Ewing’s sarcoma apoptosis and ferroptosis through NPM1/YAP1 axis. Cell Death Dis. 2024;15:99. https://doi.org/10.1038/s41419-024-06485-0.CrossRefPubMedPubMedCentral

28.

Bruno S, Ghelli Luserna di Rorà A, Napolitano R, Soverini S, Martinelli G, Simonetti G. CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies. J Exp Clin Cancer Res. 2022;41:159. https://doi.org/10.1186/s13046-022-02363-9.CrossRefPubMedPubMedCentral

29.

Liu R, Liang X, Guo H, Li S, Yao W, Dong C, et al. STNM1 in human cancers: role, function and potential therapy sensitizer. Cell Signal. 2023;109:110775. https://doi.org/10.1016/j.cellsig.2023.110775.CrossRefPubMed

30.

Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, Nikolova Z, et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol. 2012;88:406–15. https://doi.org/10.1111/j.1600-0609.2012.01764.x.CrossRefPubMed

31.

Wang S-X, Ju H-Q, Liu K-S, Zhang J-X, Wang X, Xiang Y-F, et al. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Biosci Biotechnol Biochem. 2011;75:1540–5. https://doi.org/10.1271/bbb.110225.CrossRefPubMed

32.

Senju M, Sueoka N, Sato A, Iwanaga K, Sakao Y, Tomimitsu S, et al. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol. 2006;132:150–8.CrossRefPubMed

33.

Lee YC, Chang WW, Chen YY, Tsai YH, Chou YH, Tseng HC, Chen HL, Wu CC, Chang-Chien J, Lee HT, Yang HF. Hsp90α mediates BMI1 expression in breast cancer stem/progenitor cells through facilitating nuclear translocation of c-Myc and EZH2. Int J Mol Sci. 2017;18(9):1986.CrossRefPubMedPubMedCentral

34.

Zhao Q, Zhao R, Song C, Wang H, Rong J, Wang F, et al. Increased IGFBP7 expression correlates with poor prognosis and immune infiltration in gastric cancer. J Cancer. 2021;12:1343–5. https://doi.org/10.7150/jca.50370.CrossRefPubMedPubMedCentral

35.

Baldari S, Ubertini V, Garufi A, D’Orazi G, Bossi G. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications. Cell Death Dis. 2015;6:e1621.CrossRefPubMedPubMedCentral

36.

Liu S, Li B, Xu J, Hu S, Zhan N, Wang H, et al. SOD1 promotes cell proliferation and metastasis in non-small cell lung cancer via an miR-409-3p/SOD1/SETDB1 epigenetic regulatory feedforward loop. Front Cell Dev Biol. 2020;8:213. https://doi.org/10.3389/fcell.2020.00213.CrossRefPubMedPubMedCentral

37.

Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow C-W, et al. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013;19:3383–95. https://doi.org/10.1158/1078-0432.Ccr-13-0341.CrossRefPubMed

38.

Wolvetang EJ, Wilson TJ, Sanij E, Busciglio J, Hatzistavrou T, Seth A, et al. ETS2 overexpression in transgenic models and in down syndrome predisposes to apoptosis via the p53 pathway. Hum Mol Genet. 2003;12:247–55. https://doi.org/10.1093/hmg/ddg015.CrossRefPubMed

39.

Lin H, Liu S, Gao W, Liu H. DDIT3 modulates cancer stemness in gastric cancer by directly regulating CEBPβ. J Pharm Pharmacol. 2020;72:807–15. https://doi.org/10.1111/jphp.13243.CrossRefPubMed

40.

Zheng X, Chen K, Liu X, Jiang G, Liu H. High expression of ERCC5 predicts a poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 2018;11:3664–70.PubMedPubMedCentral

41.

Kontsioti F, Maratou E, Bouhla A, Mpakou V, Thomopoulos T, Stavroulaki G, et al. PB1703 PPP1R15A gene is overexpressed in chemoresistant acute myeloid leukemia (Aml). HemaSphere. 2019;3:784–5. https://doi.org/10.1097/01.HS9.0000565328.28450.f4.CrossRef

42.

Tamura RE, de Vasconcellos JF, Sarkar D, Libermann TA, Fisher PB, Zerbini LF. GADD45 proteins: central players in tumorigenesis. Curr Mol Med. 2012;12:634–51. https://doi.org/10.2174/156652412800619978.CrossRefPubMedPubMedCentral

43.

Assis J, Pereira D, Medeiros R. Ovarian cancer and DNA repair: DNA ligase IV as a potential key. World J Clin Oncol. 2013;4:14–24. https://doi.org/10.5306/wjco.v4.i1.14.CrossRefPubMedPubMedCentral

44.

Lammens T, Swerts K, Derycke L, De Craemer A, De Brouwer S, De Preter K, et al. N-cadherin in neuroblastoma disease: expression and clinical significance. PLoS ONE. 2012;7:e31206.CrossRefPubMedPubMedCentral

45.

Yang L, Chen Y, Cui T, Knösel T, Zhang Q, Albring KF, et al. Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer. Carcinogenesis. 2012;33:1863–70. https://doi.org/10.1093/carcin/bgs226.CrossRefPubMed

46.

Vrenken KS, Vervoort BMT, van Ingen Schenau DS, Derks YHW, van Emst L, Grytsenko PG, et al. The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy. Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease. 2020. https://doi.org/10.1016/j.bbadis.2019.165644.CrossRefPubMed

47.

Bahmad HF, Thiravialingam A, Sriganeshan K, Gonzalez J, Alvarez V, Ocejo S, et al. Clinical significance of SOX10 expression in human pathology. Curr Issues Mol Biol. 2023;45:10131–58. https://doi.org/10.3390/cimb45120633.CrossRefPubMedPubMedCentral

48.

Hartwell KA, Muir B, Reinhardt F, Carpenter AE, Sgroi DC, Weinberg RA. The spemann organizer gene, goosecoid, promotes tumor metastasis. Proc Natl Acad Sci USA. 2006;103:18969–74. https://doi.org/10.1073/pnas.0608636103.CrossRefPubMedPubMedCentral

49.

Zhang L, He Y, Tu X, Wang C, Ding X, Ye R, et al. FOXC2 as a prognostic marker and a potential molecular target in patients with human solid tumors. Front Surg. 2022;9:960698.CrossRefPubMedPubMedCentral

50.

Nitti M, Ivaldo C, Traverso N, Furfaro AL. Clinical significance of heme oxygenase 1 in tumor progression. Antioxidants (Basel). 2021. https://doi.org/10.3390/antiox10050789.CrossRefPubMed

51.

Min KW, Kim DH, Son BK, Moon KM, Kim SM, Intazur Rahaman M, Kim SW, Kim EK, Kwon MJ, Koh YW, Oh IH. High SLC2A1 expression associated with suppressing CD8 T cells and B cells promoted cancer survival in gastric cancer. PLoS ONE. 2021. https://doi.org/10.1371/journal.pone.0245075.CrossRefPubMedPubMedCentral

52.

Dungwa JV, Hunt LP, Ramani P. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Hum Pathol. 2012;43:1651–60. https://doi.org/10.1016/j.humpath.2011.12.006.CrossRefPubMed

53.

Song J, Sun H, Zhang S, Shan C. The multiple roles of glucose-6-phosphate dehydrogenase in tumorigenesis and cancer chemoresistance. Life (Basel). 2022. https://doi.org/10.3390/life12020271.CrossRefPubMedPubMedCentral

54.

Talapatra J, Reddy MM. Lipid metabolic reprogramming in embryonal neoplasms with MYCN amplification. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15072144.CrossRefPubMed

55.

Zhang S, Hua Z, Ba G, Xu N, Miao J, Zhao G, et al. Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL. Cancer Cell Int. 2021;21:619. https://doi.org/10.1186/s12935-021-02330-y.CrossRefPubMedPubMedCentral

56.

Majercikova Z, Dibdiakova K, Gala M, Horvath D, Murin R, Zoldak G, et al. Different approaches for the profiling of cancer pathway-related genes in glioblastoma cells. Int J Mol Sci. 2022;23:10883.CrossRefPubMedPubMedCentral

57.

Zamudio-Martinez E, Herrera-Campos AB, Muñoz A, Rodríguez-Vargas JM, Oliver FJ. Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities. J Exp Clin Cancer Res. 2021;40:144. https://doi.org/10.1186/s13046-021-01950-6.CrossRefPubMedPubMedCentral

58.

Wang XH, Zhang SF, Wu HY, Gao J, Wang L, Wang XH, Gao TH. miRNA326-5p targets DKC1 gene to regulate apoptosis-related proteins and intervene in the development of neuroblastoma. Anal Cell Pathol. 2023. https://doi.org/10.1155/2023/6761894.CrossRef

59.

Villa R, Folini M, Porta CD, Valentini A, Pennati M, Daidone MG, et al. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis. 2003;24:851–9. https://doi.org/10.1093/carcin/bgg028.CrossRefPubMed

60.

Lampros M, Vlachos N, Voulgaris S, Alexiou GA. The Role of Hsp27 in chemotherapy resistance. Biomedicines. 2022;10:897.CrossRefPubMedPubMedCentral

61.

Zhou ZB, Huang GX, Lu JJ, Ma J, Yuan QJ, Cao Y, et al. Up-regulation of heat shock protein 27 inhibits apoptosis in lumbosacral nerve root avulsion-induced neurons. Sci Rep. 2019;9:11468. https://doi.org/10.1038/s41598-019-48003-9.CrossRefPubMedPubMedCentral

62.

Mahalingam D, Swords R, Carew JS, Nawrocki S, Bhalla K, Giles F. Targeting HSP90 for cancer therapy. Br J Cancer. 2009;100:1523–9.CrossRefPubMedPubMedCentral

63.

Lee CH, Hong HM, Chang YY, Chang WW. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. Biochimie. 2012;94(6):1382–9.CrossRefPubMed

Title: Molecular pathway of anticancer effect of next-generation HSP90 inhibitors XL-888 and Debio0932 in neuroblastoma cell line
Authors: Özlem Kaplan
Nazan Gökşen Tosun
Publication date: 01-08-2024
Publisher: Springer US
Keywords: Neuroblastoma
Neuroblastoma
Published in: Medical Oncology / Issue 8/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-024-02428-z

A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure

Pancreatic Cancer
Original Paper

Which drug would be more effective in treating patients with leptomeningeal metastases from breast cancer: intrathecal thiotepa or methotrexate?

Methotrexate
Letter to Editor

Utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in elderly patients: a retrospective cohort study

Cytostatic Therapy
Original Paper

Anti-cancer potential of casein and its derivatives: novel strategies for cancer treatment

Open Access
Breast Cancer
Review Article

Genipin’s potential as an anti-cancer agent: from phytochemical origins to clinical prospects

Pharmacokinetics
Review

Therapeutic and diagnostic applications of exosomes in colorectal cancer

Colorectal Cancer
Review Article

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Live
Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital

Prof. Ronald F. van Vollenhoven

Developed by: Springer Medicine

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Molecular pathway of anticancer effect of next-generation HSP90 inhibitors XL-888 and Debio0932 in neuroblastoma cell line

Abstract

Other articles of this Issue 8/2024

A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure

Which drug would be more effective in treating patients with leptomeningeal metastases from breast cancer: intrathecal thiotepa or methotrexate?

Utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in elderly patients: a retrospective cohort study

Anti-cancer potential of casein and its derivatives: novel strategies for cancer treatment

Genipin’s potential as an anti-cancer agent: from phytochemical origins to clinical prospects

Therapeutic and diagnostic applications of exosomes in colorectal cancer

Women’s health knowledge hub

Keynote webinar | Spotlight on advances in lupus

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Abstract

Please log in to get access to this content